Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.50 USD
+0.03 (1.22%)
Updated Apr 18, 2024 03:06 PM ET
4-Sell of 5 4
D Value B Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Minerva Neurosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 41 | 36 | 61 | 25 | 46 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 4 | 1 | 2 | 1 |
Total Current Assets | 42 | 40 | 62 | 27 | 47 |
Net Property & Equipment | 0 | 0 | 0 | 15 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 15 | 15 | 15 | 15 | 15 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 57 | 55 | 77 | 58 | 78 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 0 | 1 | 2 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 3 | 1 | 3 | 3 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 2 | 43 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 82 | 74 | 66 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 85 | 75 | 69 | 5 | 50 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 368 | 347 | 343 | 337 | 315 |
Retained Earnings | -397 | -367 | -335 | -285 | -287 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -28 | -20 | 8 | 53 | 28 |
Total Liabilities & Shareholder's Equity | 57 | 55 | 77 | 58 | 78 |
Total Common Equity | -28 | -20 | 8 | 53 | 28 |
Shares Outstanding | 6.90 | 5.30 | 5.30 | 5.30 | 4.80 |
Book Value Per Share | -4.12 | -3.78 | 1.51 | 9.94 | 5.79 |
Fiscal Year End for Minerva Neurosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 41 | 47 | 52 | 36 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 0 | 1 |
Total Current Assets | NA | 42 | 48 | 52 | 37 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 15 | 15 | 15 | 15 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 57 | 63 | 67 | 52 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 1 | 0 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 2 | 2 | 2 | 2 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 3 | 2 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 80 | 78 | 76 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 85 | 83 | 80 | 78 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 368 | 368 | 367 | 347 |
Retained Earnings | NA | -397 | -388 | -380 | -374 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -28 | -20 | -13 | -27 |
Total Liabilities & Shareholder's Equity | NA | 57 | 63 | 67 | 52 |
Total Common Equity | 0 | -28 | -20 | -13 | -27 |
Shares Outstanding | 6.90 | 6.90 | 6.90 | 6.90 | 5.30 |
Book Value Per Share | 0.00 | -4.12 | -2.91 | -1.81 | -5.02 |